Lunula laser ROI: is it worth the investment for your clinic?

Reported annual returns from small, medium and large Australian and New Zealand clinics running the Lunula laser, and what drives the difference.

Adding any therapeutic device to a clinic is a financial decision before it is a clinical one. The figures below come from a survey of Lunula clients across Australia and New Zealand, grouped by the socioeconomic profile of the clinic's location — which turned out to be the strongest predictor of both pricing and marketing spend.

What goes into the calculation

• Price of a treatment package — typically a course of sessions plus follow-up reviews, sold as a bundle.
• New patients acquired per month.
• One-off marketing set-up cost.
• Ongoing monthly promotional spend.
• Monthly finance cost of the device.
• Local pricing norms and patient demographics.

Reported annual returns

Interestingly, higher marketing spend did not translate into proportionally more new patients. New-patient volume stayed relatively steady across the groups; what changed was the price the local market would carry, and therefore the return.

What the strongest performers did differently

Two habits came up repeatedly. The first was expectation management — spending real consult time explaining how nail fungus spreads, how reinfection happens, and that severe cases may need more than the standard course. The second was bundling: patients billed per session attended less reliably than patients who bought a package, which hurt both outcomes and revenue.

Owners also flagged the back-office side: no consumables to stock or reconcile, minimal downtime, a two-year warranty, and a loan device from Rehacare if a unit ever needs repair so treatment schedules keep running.

Figures are averages reported by surveyed clinics and are not a projection or guarantee of returns for any individual practice.